央视网消息：秋季是易过敏的季节，很多人担心服用抗过敏药会上瘾，所以不敢长期使用，那么到底抗过敏药会不会导致上瘾 呢？ 北京大学第三医院药学部副主任药师 李潇潇：其实我们现在市场上主流的抗过敏药是有两类：第一类是（第二代）抗组胺的这 些药，包括我们平时非常熟西替利嗪、氯雷他定，这个药本身不作于我们的中枢神经系统；第二类药是我们平常会使用的一些鼻喷 的激素，那么这些激素它也是作用于局部，不进入到我们全身的循环，更加不会作用于我们的中枢神经系统。所以这类的药总体来 说都是非常安全的。 专家表示，现在使用的抗过敏药物，如抗组胺药、鼻用激素，并不会让人产生成瘾性。因此，过敏患者用药期间需避免自行停 药，以防导致过敏症状反复或加重。 不过，部分抗组胺药可能导致嗜睡、注意力不集中等问题，从事高空作业、驾驶车辆等需要高度集中注意力工作的人群使用 时，需特别注意用药安全。 ...

Core Viewpoint - Chronic sinusitis with nasal polyps is a prevalent condition in China, affecting approximately 100 million people, with 20 to 30 million patients experiencing nasal polyps, which significantly impacts their quality of life [1][2]. Group 1: Disease Prevalence and Symptoms - The prevalence of chronic sinusitis in China is estimated to be around 8%, translating to about 100 million patients [1]. - Common symptoms include nasal congestion, purulent nasal discharge, olfactory/taste reduction, and facial pain, which can severely affect patients' quality of life [1][2]. Group 2: Treatment Approaches - The primary treatment strategy combines corticosteroid medication and surgical intervention, but the management of chronic sinusitis with nasal polyps is challenging due to high recurrence rates [1][3]. - Surgical removal of nasal polyps aims to restore normal airflow and drainage, but it does not guarantee a permanent solution, necessitating ongoing medication and follow-up care [3][4]. Group 3: Advances in Treatment - The emergence of biologic therapies represents a significant advancement in treatment, allowing for more precise and effective management of the disease by targeting the underlying inflammatory mechanisms [4][5]. - Biologic agents focus on key inflammatory pathways associated with type 2 inflammation, which is relevant for patients with chronic sinusitis, nasal polyps, asthma, and other comorbidities [5].